Please assess the completion status of the following clinical trial:

Trial Title: Haelan and Nutrition in Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Anorexia (defined as \> 30mm on a visual analog scale \[VAS\] of 0 to 100mm)~2. Weight loss (defined as weight loss \> 5% within last 6 months)~3. Normal cognition (per treating physician's opinion)~4. Written informed consent~5. Advanced solid tumor (defined as locally recurrent or metastatic disease)~6. Patient must have perceived weight loss as a problem.~7. Able to maintain oral food intake within one week prior to enrollment in this study.~Exclusion Criteria:~1. Evidence of ascites (per treating physician's opinion).~2. Receiving supplementary tube feedings or parenteral nutrition~3. Known mechanical obstruction of the alimentary tract, or intractable vomiting~4. Add or change dose of the following medication within 2 weeks prior to this trial or during this trial: megestrol, corticosteroid, mirtazapine, metoclopramide and dronabinol, with the exception of pre-medication for chemotherapy (10-20 mg Decadron intavenous (IV) once and/or Reglan 10 mg IV x1 prior to chemotherapy).~5. Allergic to soy.~6. Positive pregnancy test for female patients of child-bearing potential. (Definition of child-bearing potential: not post-menopausal for past 12 months or nor surgically sterile)~7. Female patients with child bearing potential, but refuse to practice accepted methods of contraception (acceptable forms of contraception include: continuous abstinence, Depo-Provera shot, tubal ligation, NuvaRing vaginal ring, Ortho Evra skin patch, oral contraceptive, IUD-Mirena, vasectomy, male condom, diaphragm).~8. Weight less than 80 lb.~9. Patient who could not tolerate oral intake of 2 Oz. of Haelan during the taste test.~10. Diagnosed of breast cancer.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fermented Soy Supplement (Type: OTHER): 4 oz Haelan orally twice daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).